Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials.
Nanomedicine is a relatively new field that is rapidly evolving. Formulation of drugs on the nanoscale imparts many physical and biological advantages. Such advantages can in turn translate into improved therapeutic efficacy and reduced toxicity. While approximately 50 nanotherapeutics have already entered clinical practice, a greater number of drugs are undergoing clinical investigation for a variety of indications. This review aims to examine all the nanoformulations that are currently undergoing clinical investigation and their outlook for ultimate clinical translation. WIREs Nanomed Nanobiotechnol 2017, 9:e1416. doi: 10.1002/wnan.1416 For further resources related to this article, please visit the WIREs website.
Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Joseph M
JM
Caster
Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Artish N
AN
Patel
Department of Medicine, Duke University, Durham, NC, USA.
Tian
T
Zhang
Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Andrew
A
Wang
D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004341:Drug Evaluation; D015507:Drugs, Investigational; D006801:Humans; D051379:Mice; D050997:Nanomedicine
D015507:Drugs, Investigational